Literature DB >> 24163790

Myocilin and Optineurin: Differential Characteristics and Functional Consequences.

Beatrice Y J T Yue1.   

Abstract

Myocilin and optineurin are two genes linked to glaucoma, a major blinding disease characterized by progressive loss of retinal ganglion cells and their axons. This review describes the characteristics of myocilin and optineurin protein products and summarizes the consequences of ectopically expressed wild type and mutant myocilin and optineurin in trabecular meshwork and/or neuronal cells. Myocilin and optineurin exhibit differential characteristics and have divergent functional consequences. They contribute to the development of glaucoma likely via distinct mechanisms.

Entities:  

Keywords:  Gene; Glaucoma; Mutation; Myocilin; Optineurin

Year:  2011        PMID: 24163790      PMCID: PMC3806134          DOI: 10.1016/j.tjo.2011.08.002

Source DB:  PubMed          Journal:  Taiwan J Ophthalmol        ISSN: 2211-5056


  48 in total

1.  Adult-onset primary open-angle glaucoma caused by mutations in optineurin.

Authors:  Tayebeh Rezaie; Anne Child; Roger Hitchings; Glen Brice; Lauri Miller; Miguel Coca-Prados; Elise Héon; Theodore Krupin; Robert Ritch; Donald Kreutzer; R Pitts Crick; Mansoor Sarfarazi
Journal:  Science       Date:  2002-02-08       Impact factor: 47.728

2.  Interaction of recombinant myocilin with the matricellular protein SPARC: functional implications.

Authors:  José-Daniel Aroca-Aguilar; Francisco Sánchez-Sánchez; Sikha Ghosh; Ana Fernández-Navarro; Miguel Coca-Prados; Julio Escribano
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-01-05       Impact factor: 4.799

3.  Interaction of an adenovirus E3 14.7-kilodalton protein with a novel tumor necrosis factor alpha-inducible cellular protein containing leucine zipper domains.

Authors:  Y Li; J Kang; M S Horwitz
Journal:  Mol Cell Biol       Date:  1998-03       Impact factor: 4.272

4.  Identification of a gene that causes primary open angle glaucoma.

Authors:  E M Stone; J H Fingert; W L Alward; T D Nguyen; J R Polansky; S L Sunden; D Nishimura; A F Clark; A Nystuen; B E Nichols; D A Mackey; R Ritch; J W Kalenak; E R Craven; V C Sheffield
Journal:  Science       Date:  1997-01-31       Impact factor: 47.728

5.  Rho GTPase and cAMP/protein kinase A signaling mediates myocilin-induced alterations in cultured human trabecular meshwork cells.

Authors:  Xiang Shen; Takahisa Koga; Bum-Chan Park; Nirmala SundarRaj; Beatrice Y J T Yue
Journal:  J Biol Chem       Date:  2007-11-05       Impact factor: 5.157

6.  Impairment of protein trafficking upon overexpression and mutation of optineurin.

Authors:  BumChan Park; Hongyu Ying; Xiang Shen; Jeong-Seok Park; Ye Qiu; Rajalekshmy Shyam; Beatrice Y J T Yue
Journal:  PLoS One       Date:  2010-07-12       Impact factor: 3.240

7.  Overexpression of myocilin in cultured human trabecular meshwork cells.

Authors:  Kelly Wentz-Hunter; Xiang Shen; Kazushiro Okazaki; Hidenobu Tanihara; Beatrice Y J T Yue
Journal:  Exp Cell Res       Date:  2004-07-01       Impact factor: 3.905

8.  Extracellular myocilin affects activity of human trabecular meshwork cells.

Authors:  Kelly Wentz-Hunter; Ryo Kubota; Xiang Shen; Beatrice Y J T Yue
Journal:  J Cell Physiol       Date:  2004-07       Impact factor: 6.384

9.  Optineurin negatively regulates TNFalpha- induced NF-kappaB activation by competing with NEMO for ubiquitinated RIP.

Authors:  Guozhi Zhu; Chuan-Jin Wu; Yongge Zhao; Jonathan D Ashwell
Journal:  Curr Biol       Date:  2007-08-21       Impact factor: 10.834

10.  NF-kappaB mediates tumor necrosis factor alpha-induced expression of optineurin, a negative regulator of NF-kappaB.

Authors:  Cherukuri Sudhakar; Ananthamurthy Nagabhushana; Nishant Jain; Ghanshyam Swarup
Journal:  PLoS One       Date:  2009-04-02       Impact factor: 3.240

View more
  1 in total

1.  Cellular processing of myocilin.

Authors:  Ye Qiu; Xiang Shen; Rajalekshmy Shyam; Beatrice Y J T Yue; Hongyu Ying
Journal:  PLoS One       Date:  2014-04-14       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.